| Title: |
Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course |
| Authors: |
Angotzi, Francesco; Cellini, Alessandro; Ruocco, Valeria; Cavarretta, Chiara Adele; Zatta, Ivan; Serafin, Andrea; Pravato, Stefano; Pagnin, Elisa; Bonaldi, Laura; Frezzato, Federica; Facco, Monica; Piazza, Francesco; Trentin, Livio; Visentin, Andrea |
| Contributors: |
Angotzi, Francesco; Cellini, Alessandro; Ruocco, Valeria; Cavarretta, Chiara Adele; Zatta, Ivan; Serafin, Andrea; Pravato, Stefano; Pagnin, Elisa; Bonaldi, Laura; Frezzato, Federica; Facco, Monica; Piazza, Francesco; Trentin, Livio; Visentin, Andrea |
| Publisher Information: |
MDPI |
| Publication Year: |
2024 |
| Collection: |
Padua Research Archive (IRIS - Università degli Studi di Padova) |
| Subject Terms: |
borderline mutated; chronic lymphocytic leukemia; IGHV mutational statu |
| Description: |
Chronic lymphocytic leukemia (CLL) exhibits substantial variability in disease course. The mutational status of the B-cell receptor immunoglobulin heavy variable (IGHV) chain is a critical prognostic factor, categorizing patients into mutated (M-IGHV) and unmutated (U-IGHV) groups. Recently, a third subgroup with borderline mutational status (BL-IGHV) has been identified, comprising approximately 5% of CLL cases. This study retrospectively analyzes the outcomes of 30 BL-IGHV mutated patients among a cohort of 653 CLL patients, focusing on time to first treatment (TTFT) and overall survival (OS). BL-IGHV patients had a short TTFT similar to U-IGHV patients (median 30.2 vs. 34 months; p = 0.9). Conversely, the OS of BL-IGHV patients resembled M-IGHV patients (median NR vs. 258 months; p = 1). Despite a similar incidence in unfavorable prognostic factors, the TTFT was shorter compared to other published cohorts. However, striking similarities with other experiences suggest that BL-IGHV mutated patients share common biological characteristics, biased IGHV gene usage and BCR subset frequency. These findings also underscore the need for multicentric efforts aggregating data on BL-IGHV CLL in order to elucidate its disease course and optimize therapeutic approaches for this rare subgroup. Until then, predicting outcomes and optimal management of BL-IGHV CLL will remain challenging. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/wos/WOS:001191683300001; volume:16; issue:6; journal:CANCERS; https://hdl.handle.net/11577/3509582 |
| DOI: |
10.3390/cancers16061095 |
| Availability: |
https://hdl.handle.net/11577/3509582; https://doi.org/10.3390/cancers16061095 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.ECA4E49 |
| Database: |
BASE |